Question · asked by 1 review

Large‐volume residual disease (LVRD) > 1 cm vs NMRD: Progression‐free survival

Large‐volume residual disease (LVRD) > 1 cm probably leads to higher progression‐free survival: Median length of compared with no macroscopic residual disease (NMRD) (moderate certainty).

What each review found

Include earlier review versions
FindingEffectStudiesGRADE certainty
Large‐volume residual disease (LVRD) > 1 cm vs no macroscopic residual disease (NMRD)
Progression‐free survival: Median length of · women with advanced ovarian cancer after PDS
Large‐volume residual disease (LVRD) > 1 cm probably leads to higher progression‐free survival: Median length of compared with no macroscopic residual disease (NMRD) (moderate certainty).
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian… (2022) · Cochrane Headline outcomes only
HR 2.1 [1.84, 2.4]6 studies · 2629 participantsModerate

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery
2022 · Cochrane Headline outcomes only
Not reportedlist not extracted yetNot assessed

Studies behind the findings

None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.